BC Innovations | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
BC Innovations | Feb 5, 2019
Distillery Therapeutics


INDICATION: Autism Mouse studies suggest inhibiting P2RX7 could help treat autism. In a mouse model of autism, systemic knockout of P2RX7 or a tool compound P2RX7 inhibitor tool decreased social deficits, sensorimotor coordination impairment and...
BC Innovations | Sep 26, 2018
Distillery Techniques


TECHNOLOGY: SNPs A SNP on P2RX7 could help predict outcomes in heart transplant patients. In 102 heart transplant patients, P2RX7 genotyping identified an association between a SNP on P2RX7 (rs3751143) and the risk of rapidly...
BC Innovations | Aug 16, 2018
Distillery Therapeutics


INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
BioCentury | May 18, 2018

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Innovations | Jan 23, 2018
Distillery Therapeutics


INDICATION: Graft rejection Patient sample and mouse studies suggest inhibiting P2RX7 could help treat transplant rejection. In blood samples from liver transplant patients, monocyte levels of P2RX7 were higher in patients who rejected their transplants...
BC Innovations | May 24, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient samples, cell culture, and mouse studies suggest P2RX7 inhibitors could help treat diabetic nephropathy. In glomeruli samples from diabetes patients, P2RX7 expression was higher in patients with nephropathy than in patients without...
BC Innovations | Jan 3, 2017
Distillery Therapeutics

Inflammation; dermatology; renal

INDICATION: Inflammation; dermatitis; glomerulonephritis Cell culture, human sample and mouse studies identified anti- P2RX7 nanobodies that could help treat allergic contact dermatitis, glomerulonephritis and other inflammatory diseases. Screening of nanobody libraries from P2RX7-immunized llamas, engineering...
BC Innovations | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7)

Infectious disease INDICATION: HIV / AIDS Cell culture studies suggest P2RX7 inhibitors or imipramine could help treat HIV infection. In an assay of ATP-stimulated virion release in HIV-infected human macrophage cell lines, a research-grade inhibitor...
BioCentury | May 25, 2015

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
Items per page:
1 - 10 of 51